Search PubMed⌕ Search

Biomedical subjects

J Pont

Publications and source records attributed to J Pont.

65 records · Page 4Linked to original sources
PubMedDate not supplied

Antibody prevalence of parenterally transmitted viruses (HIV-1, HTLV-I, HBV, HCV) in Austrian intravenous drug users.

UNLABELLED: From 1985 to 1990 the sera of 372 newly imprisoned intravenous drug users (IDU) were tested for HIV-1 antibodies. The seroprevalence was 18%, males 16% and females 31%. HIV-1 seroprevalence in Austrian IDU has not increased since 1986. All sera tested for HTLV-I-antibodies were negative. The majority of the HIV-1 seropositive drug users had been infected before 1985. The reported frequency of needle sharing has decreased since 1986. Of 151 IDU tested for HCV antibodies 75% were positive for anti-HCV, 68% were positive for hepatitis B markers, 59% were positive for both HBV and HCV markers, and 13% were positive for HIV-1 antibodies. IN CONCLUSION: in Austrian IDU HCV seems to be the most frequent parenterally transmitted virus; HIV-1 seroprevalence has not increased since 1986; HLTV-I infection has not yet begun.

Adolescent↗
PubMedDate not supplied

Cefaclor-associated serum sickness-like disease: eight cases and review of the literature.

OBJECTIVE: To describe the clinical features of serum sickness-like diseases (SSLD) in cefaclor-treated patients. DESIGN: Analysis of a case series spontaneously reported to Lyons Pharmacovigilance Center. SETTING: General and hospital practitioners and the French Network of Regional Pharmacovigilance Centers (FNRPC). PATIENTS: All reported cases with a possible causative relationship between cefaclor treatment and SSLD. MAIN RESULTS: Eight cases of SSLD following cefaclor treatment are described. The clinical features included cutaneous reactions, arthralgias, and moderate hyperthermia. In 50 percent of the patients, hospitalization was required because of incapacitating symptoms. The outcome was benign in all cases following discontinuation of the offending drug. All eight cases were reported in children under five years of age. Among 137 cefaclor-associated drug reactions collected by FNRPC, 27 cases of SSLD have been reported; 23 of these patients were younger than five years of age. A literature survey confirmed the higher reporting of SSLD in children with cefaclor compared with other antibiotics and suggested an incidence of 0.024-0.2 percent of SSLD per drug course of cefaclor. CONCLUSIONS: The case reports and epidemiologic studies confirmed the presumed role of age (patients under five years of age) in cefaclor-induced SSLD and the benign outcome despite severe clinical presentations in some reports.

Cefaclor↗
PubMedDate not supplied

Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.

The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.

Adolescent↗